IMMUNE CHECKPOINT INHIBITORS MARKET ANALYSIS

Market Challenges And Opportunities

Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.

• Introduction of novel immune checkpoint inhibitors with less side effects
• Increasing approval of the Immune Checkpoint Inhibitors by the regulatory bodies

• High cost of immuno-oncology therapies, which is unaffordable to low and middle income population

The major factors that hinder growth of the global immune checkpoint inhibitors market include high cost of immuno-oncology therapies, which is unaffordable to low and middle income population. For instance, in January 2018, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer cost around US$ 2,250 for a vial of 50 mg.

Increasing approval of the Immune Checkpoint Inhibitors by the regulatory bodies is expected to drive the global immune checkpoint market

Increasing approval of the Immune Checkpoint Inhibitors by the regulatory bodies is expected to drive the global immune checkpoint market over the forecast period. For instance, in August 2021, GSK plc., Pharmaceutical and Biotechnology Company, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline’s PD-1 checkpoint inhibitor Jemperli (dostarlimab) for adults with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer. Jemperli is an anti-PD-1 antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. The drug was discovered by AnaptysBio and licensed to Tesaro in March 2014. GSK completed its acquisition of Tesaro in January 2019.

Increasing approval of the Immune Checkpoint Inhibitors by the regulatory bodies is expected to drive the global immune checkpoint market over the forecast period. For instance, in August 2021, GSK plc., Pharmaceutical and Biotechnology Company, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline’s PD-1 checkpoint inhibitor Jemperli (dostarlimab) for adults with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer. Jemperli is an anti-PD-1 antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. The drug was discovered by AnaptysBio and licensed to Tesaro in March 2014. GSK completed its acquisition of Tesaro in January 2019.